Evaluation of Galcanezumab in the Prevention of Chronic Migraine

NCT02614261 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1117

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Migraine

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company